Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Revenue (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Revenue data on record, last reported at $820188.0 in Q4 2025.

  • For Q4 2025, Revenue fell 26.22% year-over-year to $820188.0; the TTM value through Dec 2025 reached $4.5 million, down 6.73%, while the annual FY2025 figure was $4.9 million, 7.5% up from the prior year.
  • Revenue reached $820188.0 in Q4 2025 per INM's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Revenue topped out at $2.3 million in Q2 2023 and bottomed at $265092.0 in Q4 2021.
  • Average Revenue over 5 years is $982686.4, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Revenue: soared 348.96% in 2023, then tumbled 44.48% in 2024.
  • A 5-year view of Revenue shows it stood at $265092.0 in 2021, then surged by 77.22% to $469783.0 in 2022, then skyrocketed by 163.99% to $1.2 million in 2023, then dropped by 10.36% to $1.1 million in 2024, then decreased by 26.22% to $820188.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $820188.0 in Q4 2025, $1.1 million in Q3 2025, and $1.3 million in Q2 2025.